NYZL1 Pep-LNP
Cat. No.: TDLD-0825-LD96
NYZL1 Pep-LNP
NYZL1 Pep-LNP is a state-of-the-art peptide-functionalized lipid nanoparticle (LNP), designed for efficient targeted delivery of therapeutic cargoes such as siRNA, mRNA, DNA, small molecule drugs, and RNA-guided gene editing systems. Engineered with the NYZL1 peptide, which exhibits significant specific binding to bladder cancer tissues and cells, this LNP offers enhanced specificity for these targets. Our LNP is prepared using Targeting Module and a variety of optional lipid formulations including DLin-MC3-DMA, LP-01, ALC-0315, SM102, and others. These formulations are carefully selected to ensure the LNP has uniform particle size, high encapsulation efficiency, stability, and targeted delivery. Applications of NYZL1 Pep-LNP include targeted therapy for bladder cancer, developing NYZL1-specific imaging agents for early detection or monitoring, and studying the biology of bladder cancer cells and potential drug delivery mechanisms. Please note that this product is intended for research purposes only.
| Payload Type | mRNA |
| Payload | Empty; EGFP mRNA; Firefly Luciferase mRNA; mCherry mRNA; GFP mRNA; OVA mRNA; EPO mRNA; Renilla Luciferase mRNA; Gaussia Luciferase mRNA; Beta-galactosidase mRNA; Cre mRNA; mOrange mRNA; tdTomato mRNA; EYFP mRNA; Others |
| Capping | Cap 1 |
| Modification | Unmodified; N1-methyl-pseudouridine; 5-methoxyuridine; Other |
| Module Type | Peptide |
| Targeting Module | NYZL1 Peptide |
| LNP Type | Pep-LNP; Empty LNP; mRNA-LNP |
| Target | Bladder |
| Lipid Formulation | DLin-MC3-DMA; LP-01; ALC-0315; SM102; Other |
| Dye | Unlabeled; DiR; DiD; DiO; DiI; Other |
| Application | Targeted Delivery; Gene Therapy |
| Format | Liquid |
| Concentration | 0.1 mg/mL; 0.2 mg/mL; Other (Please Specify) |
| Size | 65-120 nm |
| PDI | < 0.2 |
| Zeta | ± 20.0 mV |
| Encapsulate Efficiency | >90% |
| Shipping | Dry Ice |
| Storage | Store at -80°C |
Click the button below to contact us or submit your feedback about this product.
